Cme-lem4 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 117 | 脊髄空洞症 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-002383-16-ES (EUCTR) | 19/01/2016 | 15/10/2015 | Evaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyelia | Evaluate the efficacy of the cell therapy with NC1 medication in patients with post-traumatic syringomyelia | Traumatic spinal cord injury, chronically established, associated with syringomyelia and neurological deficit considered irreversible.;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Células mesenquimales troncales adultas autólogas de medula ósea expandidas Product Code: CME-LEM4 INN or Proposed INN: células mesenquimales troncales adultas autólogas de médula ósea expandidas | Fundación Investigación Biomédica Hospital Universitario Puerta de Hierro | NULL | Not Recruiting | Female: yes Male: yes | 6 | Phase 2 | Spain |